NeuroOne Medical Technologies Corporation (Nasdaq: NMTC), a medical technology company focused on neurological disorders, announced an equity inducement grant to a new employee under its 2021 Inducement Plan, effective June 24, 2026. The grant, approved by independent directors in accordance with Nasdaq Listing Rule 5635(c)(4), is a material inducement for the individual to join the company. This move underscores NeuroOne's strategy to attract key talent to support its growing pipeline of surgical solutions.
The new hire, who was not a previous employee or director, received an option to purchase 10,000 shares of NeuroOne's common stock at an exercise price of $3.27 per share, the closing price on the grant date. The option has a ten-year term and vests over four years, with 25% vesting on June 24, 2027, and the remainder in 12 equal quarterly installments, contingent on continued employment. Such inducement grants are common for emerging medical technology companies to secure experienced professionals without prior stockholder-approved plans.
NeuroOne's technology platform includes FDA-cleared products like Evo® Cortical Electrodes, Evo® sEEG Electrodes, OneRF® Ablation System, and OneRF® Trigeminal Nerve Ablation System. These minimally invasive solutions aim to reduce hospitalizations and surgical procedures while improving patient outcomes. The company also advances research in drug delivery, basivertebral nerve ablation, and spinal cord stimulation. The inducement grant reflects confidence in its growth trajectory, as it seeks to commercialize these innovations and expand its market presence.
The grant is significant as it highlights NeuroOne's need for specialized talent to navigate regulatory, clinical, and commercial challenges. By leveraging Nasdaq Rule 5635(c)(4), the company can offer competitive compensation to attract experts who can drive its mission. This approach is particularly relevant for smaller med-tech firms that rely on inducement grants to build teams without diluting shareholder-approved plans prematurely.
The option's vesting schedule aligns with long-term retention, ensuring the new hire contributes to key milestones, such as FDA approvals or product launches. As NeuroOne continues research and development, this grant may signal upcoming advancements in its pipeline. The company's focus on neurological disorders, including epilepsy and chronic pain, positions it in a high-demand market, making talent acquisition critical for sustained innovation and competitive advantage.
